

Huntington Disease (HD)

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

Trial Status
Completed

Trial Runs In
18 Countries

Trial Identifier
NCT03761849 2018-002987-14
BN40423

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease

Trial Summary:

This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in participants with manifest Huntington's disease (HD)

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT03761849 2018-002987-14 BN40423
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
#25 Years & # 65 Years

Healthy Volunteers
No

Inclusion Criteria:

- Manifest HD diagnosis, defined as a DCL score of 4
- Independence Scale (IS) score ≥ 70
- Genetically confirmed disease by direct DNA testing with a CAP score >400

ForPatients

by Roche

- Clinical assessment to ensure individual has intact functional independence at baseline to maintain self-care and core activities of daily living (ADLs).

Exclusion Criteria:

- Any serious medical condition or clinically significant laboratory, or vital sign abnormality or claustrophobia at screening that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
- Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study drug